by Sue Robbins | Nov 2, 2020 | Migraine
Treatment with fremanezumab, the fully humanized IgG2?a monoclonal antibody that selectively targets calcitonin gene-related peptide, significantly reduced the number of headache or migraine days experienced before therapy. These findings, from a pooled analysis of...
by Sue Robbins | Oct 28, 2020 | Migraine
Fewer than one in three people with migraine took guideline-recommended prescription medication, data presented at the American Headache Society (AHS) annual scientific meeting showed. About 28% of survey respondents with mild to severe migraine-related...
by Sue Robbins | Oct 27, 2020 | Children's Pain, Miscellaneous
In a new report on pediatric pain in the British medical journal The Lancet, a commission of experts, including scientists, doctors, psychologists, parents and patients, challenged those who take care of children to end what they described as the common...
by Sue Robbins | Oct 26, 2020 | Migraine
The first dual-purpose, external trigeminal nerve stimulation device to treat and prevent acute migraine is now available over the counter to adults over age 18. The Food and Drug Administration has cleared Cefaly Dual (Cefaly Technology) which was...
by Sue Robbins | Oct 21, 2020 | Miscellaneous
People with obsessive-compulsive disorder, or OCD, report that the severity of their symptoms was reduced by about half within four hours of smoking cannabis, according to a Washington State University study. The researchers analyzed data inputted into the Strainprint...
